Bibliography

(1) Hanahan, D.; Weinberg, R. A. The hallmarks of cancer. Cell 2000, 100 (1), 57–70.

(2) Rosenberg, B.; VanCamp, L.; Trosko, J. E.; Mansour, V. H. Platinum compounds: a new class of potent antitumour agents. Nature 1969, 222 (5191), 385–386.

(3) Dasari, S.; Tchounwou, P. B. Cisplatin in cancer therapy: molecular mechanisms of action. Eur. J. Pharmacol. 2014, 740, 364–378.

(4) Dilruba, S.; Kalayda, G. V. Platinum-based drugs: past, present and future. Cancer Chemother. Pharmacol. 2016, 77 (6), 1103–1124.

(5) Johnstone, T. C.; Park, G. Y.; Lippard, S. J. Understanding and improving platinum anticancer drugs--phenanthriplatin. Anticancer Res. 2014, 34 (1), 471–476.

(6) Johnstone, T. C.; Suntharalingam, K.; Lippard, S. J. The next generation of platinum drugs: Targeted pt(II) agents, nanoparticle delivery, and pt(IV) prodrugs. Chem. Rev. 2016, 116 (5), 3436–3486.

(7) Zhou, J.; Kang, Y.; Chen, L.; Wang, H.; Liu, J.; Zeng, S.; Yu, L. The drug-resistance mechanisms of five platinum-based antitumor agents. Front. Pharmacol. 2020, 11, 343.

(8) Extrinsic Pathway of Apoptosis (Apoptosis molecular Mechanism part 2) https://www.easybiologyclass.com/extrinsic-pathway-of-apoptosis-apoptosis-molecular-mechanism-part-2/ (accessed Nov 21, 2020).

(9) Intrinsic Pathway of Apoptosis (Apoptosis molecular mechanism part 1) https://www.easybiologyclass.com/intrinsic-pathway-of-apoptosis-apoptosis-molecular-mechanism-part-1/ (accessed Nov 21, 2020).

(10) The Institute of Cancer Research. https://www.icr.ac.uk/about-us/our-achievements/our-scientific-discoveries/we-discovered-chemotherapeutic-agents-which-are-still-in-use-more-than-50-years-later. (accessed Nov 21, 2020).

(11) Monneret, C. Platinum anticancer drugs. From serendipity to rational design. Ann. Pharm. Fr. 2011, 69 (6), 286–295.

(12) Barnham, K. J.; Djuran, M. I.; Murdoch, P. del S.; Ranford, J. D.; Sadler, P. J. Ring-opened adducts of the anticancer drug carboplatin with sulfur amino acids. Inorg. Chem. 1996, 35 (4), 1065–1072.

(13) Sousa, G. F. de; Wlodarczyk, S. R.; Monteiro, G. Carboplatin: molecular mechanisms of action associated with chemoresistance. Braz. J. Pharm. Sci. 2014, 50 (4), 693–701.

(14) Thayer, A. M. Pedagogy on platinum drugs https://cen.acs.org/articles/88/i26/Pedagogy-Platinum-Drugs.html (accessed Nov 21, 2020).

(15) Graham, J.; Mushin, M.; Kirkpatrick, P. Oxaliplatin. Nat. Rev. Drug Discov. 2004, 3 (1), 11–12.

(16) Fuertes, M. A.; Alonso, C.; Pérez, J. M. Biochemical modulation of Cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance. Chem. Rev. 2003, 103 (3), 645–662.

(17) Astolfi, L.; Ghiselli, S.; Guaran, V.; Chicca, M.; Simoni, E.; Olivetto, E.; Lelli, G.; Martini, A. Correlation of adverse effects of cisplatin administration in patients affected by solid tumours: a retrospective evaluation. Oncol. Rep. 2013, 29 (4), 1285–1292.

(18) Cisplatin (Intravenous Route) https://www.mayoclinic.org/drugs-supplements/cisplatin-intravenous-route/side-effects/drg-20062953 (accessed Nov 21, 2020).

(19) Kelland, L. The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer 2007, 7 (8), 573–584.

(20) Navya, P. N.; Kaphle, A.; Srinivas, S. P.; Bhargava, S. K.; Rotello, V. M.; Daima, H. K. Current trends and challenges in cancer management and therapy using designer nanomaterials. Nano Converg. 2019, 6 (1), 23.

(21) Galluzzi, L.; Senovilla, L.; Vitale, I.; Michels, J.; Martins, I.; Kepp, O.; Castedo, M.; Kroemer, G. Molecular mechanisms of cisplatin resistance. Oncogene 2012, 31 (15), 1869–1883.

(22) Samimi, G.; Safaei, R.; Katano, K.; Holzer, A. K.; Rochdi, M.; Tomioka, M.; Goodman, M.; Howell, S. B. Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells. Clin. Cancer Res. 2004, 10 (14), 4661–4669.

(23) Li, Q.; Yu, J. J.; Mu, C.; Yunmbam, M. K.; Slavsky, D.; Cross, C. L.; Bostick-Bruton, F.; Reed, E. Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells. Anticancer Res. 2000, 20 (2A), 645–652.

(24) Yuan, M.; Luong, P.; Hudson, C.; Gudmundsdottir, K.; Basu, S. c-Abl phosphorylation of ΔNp63α is critical for cell viability. Cell Death Dis. 2010, 1 (1), e16.

(25) Coluccia, M.; Natile, G. Trans-platinum complexes in cancer therapy. Anticancer Agents Med. Chem. 2007, 7 (1), 111–123.

(26) Stathopoulos, G. P.; Boulikas, T. Lipoplatin formulation review article. J. Drug Deliv. 2012, 2012, 581363.

(27) Huo, T.; Barth, R. F.; Yang, W.; Nakkula, R. J.; Koynova, R.; Tenchov, B.; Chaudhury, A. R.; Agius, L.; Boulikas, T.; Elleaume, H.; et al. Preparation, biodistribution and neurotoxicity of liposomal cisplatin following convection enhanced delivery in normal and F98 glioma bearing rats. PLoS One 2012, 7 (11), e48752.

(28) Brunning, A. Periodic graphics: Platinum drugs for cancer https://cen.acs.org/pharmaceuticals/oncology/Periodic-graphics-Platinum-Drugs-Cancer/96/i37 (accessed Nov 21, 2020).

(29) RCSB Protein Data Bank. 1PG9 https://www.rcsb.org/structure/1PG9 (accessed Nov 21, 2020).

(30) What is Apoptosis? https://www.news-medical.net/life-sciences/What-is-Apoptosis.aspx (accessed Nov 21, 2020).

(31) National Cancer Institute’s Anticancer Drug Screen Panel https://www.researchgate.net/figure/A-comparison-of-cisplatin-and-oxaliplatin-IG50-results-on-a-standard-NCI-drug-screen_fig1_235390095 (accessed Nov 21, 2020).

(32) Rocha, C. R. R.; Silva, M. M.; Quinet, A.; Cabral-Neto, J. B.; Menck, C. F. M. DNA repair pathways and cisplatin resistance: an intimate relationship. Clinics (Sao Paulo) 2018, 73 (suppl 1), e478s.

(33) Carboplatin Cancer Drug Molecule https://fineartamerica.com/featured/carboplatin-cancer-drug-molecule-molekuul.html (accessed Nov 21, 2020).

(34) Kemocarb (Carboplatin) Injection 10mg/ml https://www.fresenius-kabi.com/sg/products/carboplatin (accessed Nov 21, 2020).

(35) Flores, A.; Klein, A.; Ramirez, M.; Adrian, R. Synthesis and infrared characterization of copper(II) terpyridine complexes https://www.uiw.edu/smse/_docs/camps/ub-sac-2019-adrian-abi-alexandra-and-maricruz.pdf (accessed Nov 21, 2020).

(36) Oxaliplatin https://www.sciencedirect.com/topics/chemistry/oxaliplatin (accessed Nov 21, 2020).

(37) Oxaliplatin https://enacademic.com/dic.nsf/enwiki/1014522 (accessed Nov 21, 2020).

(38) Oun, R.; Moussa, Y. E.; Wheate, N. J. The side effects of platinum-based chemotherapy drugs: a review for chemists. Dalton Trans. 2018, 47 (19), 6645–6653.

(39) Cisplatin and Transplatin https://upload.wikimedia.org/wikipedia/commons/thumb/5/57/Cisplatin_and_transplatin.svg/1280px-Cisplatin_and_transplatin.svg.png (accessed Nov 21, 2020).

(40) Picoplatin https://upload.wikimedia.org/wikipedia/commons/0/04/Picoplatin.png (accessed Nov 21, 2020).